Published online December 1, 2005
PEDIATRICS Vol. 116 No. 6 December 2005, pp. 1361-1366 (doi:10.1542/peds.2005-0293)

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Sperandio, M. Articles by Linderkamp, O. Search for Related Content PubMed PubMed Citation Articles by Sperandio, M. Articles by Linderkamp, O. Related Collections Premature & Newborn Social Bookmarking                         What's this?

Effectiveness and Side Effects of an Escalating, Stepwise Approach to Indomethacin Treatment for Symptomatic Patent Ductus Arteriosus in Premature Infants Below 33 Weeks of Gestation

Markus Sperandio, MD^*, Bernd Beedgen, MD^*, Reinhard Feneberg, MD^*,, Christina Huppertz, MD^*, Jürgen Brüssau, MD^*, Johannes Pöschl, MD^* and Otwin Linderkamp, MD^*

^* Division of Neonatology, Department of Pediatrics
Coordination Center for Clinical Trials, University of Heidelberg, Heidelberg, Germany

Objective. Symptomatic patent ductus arteriosus (sPDA) is a common problem in premature infants and can be treated effectively with intravenous indomethacin, leading to permanent ductal closure in 70% to 80% of infants. Infants who do not respond to pharmacologic closure of the duct ultimately have to undergo surgical or interventional closure of the PDA. Optimizing the pharmacologic treatment could offer an interesting approach to reduce the number of infants who need surgical closure of the duct.

Methods. We conducted a retrospective analysis in infants who were <33 weeks’ gestation, had sPDA, and were treated with high-dose intravenous indomethacin. From 1993 to 2002, 129 infants with sPDA received indomethacin after diagnosis of sPDA was confirmed by echocardiography. Treatment was started in all infants with intravenous indomethacin (0.2 mg/kg given 5 times at 0 hours, 12 hours, 24 hours, 48 hours, and 72 hours). When the ductus was still open at 36 hours, indomethacin every 12 hours was continued and single doses increased up to 1 mg/kg until ductal closure was achieved.

Results. In 68 (53%) of 129 infants who were treated with indomethacin, ductal closure occurred during intermediate-dose indomethacin therapy (up to 1.5 mg/kg total dose). In the 61 initial nonresponders, the continuation of indomethacin led to ductal closure in 59 infants. When infants who were treated with an intermediate dose were compared with the initial nonresponders, no differences in the incidences of renal or electrolyte abnormalities, gastrointestinal bleeding, intraventricular hemorrhage, or periventricular leukomalacia were found.

Conclusions. High-dose indomethacin after intermediate-dose therapy resulted in an overall closure rate of 98.5% (127 of 129). Although single indomethacin doses of up to 1 mg/kg were given, high-dose indomethacin was safe.

---

Key Words: patent ductus • indomethacin • premature infants

Abbreviations: sPDA, symptomatic patent ductus arteriosus • GI, gastrointestinal • NEC, necrotizing enterocolitis

---

Accepted Apr 12, 2005.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J T Attridge, D A Kaufman, and D S Lim B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2009; 94(3): F178 - F182. [Abstract] [Full Text] [PDF]

				J. C. Madan, D. Kendrick, J. I. Hagadorn, I. D. Frantz III, and the National Institute of Child Health and Human D Patent Ductus Arteriosus Therapy: Impact on Neonatal and 18-Month Outcome Pediatrics, February 1, 2009; 123(2): 674 - 681. [Abstract] [Full Text] [PDF]

				P. V. Gordon Reopening the debate on corticosteroids: to the editor. Pediatrics, June 1, 2006; 117(6): 2318 - 2320. [Full Text] [PDF]

				S. Manzar High-Dose Indomethacin for Patent Ductus Arteriosus Closure: How Strong Is the Evidence? Pediatrics, May 1, 2006; 117(5): 1863 - 1863. [Full Text] [PDF]

				M. Sperandio, B. Beedgen, and O. Linderkamp High-Dose Indomethacin for Patent Ductus Arteriosus Closure: How Strong Is the Evidence?: In Reply Pediatrics, May 1, 2006; 117(5): 1863 - 1864. [Full Text] [PDF]